Healthcare Biocon shares gain 5% on launch of Ogivri biosimilar in US Updated : December 03, 2019 11:20 AM IST Shares of Biocon rose 5 percent on Tuesday after the company launched Trastuzumab biosimilar Ogivri in the US market. The company with its partner Mylan NV announced the US launch of Ogivri. So far in 2019, Biocon has underperformed the market, falling 9 percent as compared to around 11 percent rise in the benchmark Nifty50. Subscribe to Moneycontrol PRO at just Rs.33/- per month for the first year. Use code SUPERPRO. Limited period offer. Available on Web and Android.